On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Flow’s headset is the first tDCS device approved by the FDA ...

-- Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 7 (p=0.0094) -- -- Demonstrated Rapid and Durable ...

Almost half of people with depression meet criteria for being ‘treatment-resistant’, found a new study published in the British Journal of Psychiatry. Definitions for treatment-resistant depression ...

– Successful outcome from recent FDA meeting guides Alto’s plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to ...

Major depression is not only a crisis of mood, it is also a crisis of biology that reshapes the brain itself. As genetic ...

– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – ...

This collaboration sets out to explore whether using the Matter Neuroscience protocol combined with real-time neurofeedback can influence emotional brain networks relevant to depression. PALO ALTO, ...

Exercise reduces symptoms of depression and anxiety in children and adolescents reported a new study published in the Journal of the American Academy of Child & Adolescent Psychiatry. “Exercise is a ...

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting – Successful outcome from recent FDA ...

The MarketWatch News Department was not involved in the creation of this content. -- Met Primary Endpoint with 30mg Dose of RE104 with 23.0-Point Total Score Reduction in Montgomery-Åsberg Depression ...